Comparative Pharmacology
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus TRIOSTAT.
LIOTHYRONINE SODIUM vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone